Avalo Therapeutics, Inc.

US$6.93As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:AVTXHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (51.95%)
Div yield —
ROE (33.57%)
Biotechnology
Beta (5Y) 0.74
PE TTM —
TSR TTM (61.56%)
Mkt cap US$400.7M
ROIC (206.93%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$6.67
(3.69%)
204.53%
Hold 3|7|12|6|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.09
0.09
0.09
0.10
15.24%
6.33%
1.94%
15.06%
Revenue$M
18.59
19.28
19.64
20.45
(0.82%)
3.71%
6.60%
9.70%
Peers (US$400.7M)
Cap (US$)
PE
404.6M
—
Capital
TTM
5Y
10Y
Leveragex
3.034
0.983
1.004
EBIT/Intx
0.801
0.224
0.198
Own earn%
117.59
231.34
225.42
Sh yield%
31.87
25.31
24.56
Owners
Insiders/Inst%
6.51
87.99
Short interest%
1.68
SBC / revenue%
0.70
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
25
Op margin range%
16–24
$1 testx
—
Incr. ROIC%
2